Introduction {#s1}
============

Previous trials combined genotype 2 (GT2) and GT3 patients as an "easy to treat" group and guidelines recommend similar treatment for both genotypes [@pone.0107592-Sarrazin1]--[@pone.0107592-Mangia2]. Recently it has been suggested that the two genotypes differ and need more specific management [@pone.0107592-Mecenate1]--[@pone.0107592-Probst1]. Even after the approval of sofosbuvir by FDA and EMA the combination therapy with pegylated interferon and ribavirin will stay an important treatment option for patients infected with GT2 and GT3 in many parts of the world. The present study looks for differences between these genotypes and analyzes predictive factors for sustained virological response (SVR) after treatment with pegylated interferon and ribavirin under real-life conditions.

Methods {#s2}
=======

The study was approved by health authorities and the ethical committee Ethik-Kommission der Ärztekammer Westfalen-Lippe, Münster, Germany. This study and all related studies for this drug are registered in the national register for non-interventional studies at vfa (Verband Forschender Arzneimittelhersteller e.V., Berlin, Germany). Written informed consent was obtained from all patients. The protocol for this trial and the supporting TREND checklist are available as supporting information; see [Checklist S1](#pone.0107592.s002){ref-type="supplementary-material"} and [Protocol S1](#pone.0107592.s003){ref-type="supplementary-material"}.

Patients {#s2a}
--------

In the ongoing observational study ML21645, 9,679 patients with chronic hepatitis C were treated with PEG-IFN α2a and ribavirin (Pegasys, Roche Pharma AG, Grenzach-Wyhlen, Germany in combination with different, in Germany approved and available ribavirins) between August 2007 and July 2012. The present analysis includes all 2,347 patients with untreated GT2 (n = 391) and GT3 (n = 1,956) infection who had a follow-up of at least 24 weeks after end of the antiviral therapy by July 2012 in order to assess SVR24. GT1 data of this cohort have been published previously [@pone.0107592-Hppe1]--[@pone.0107592-Niederau2]. Throughout Germany, 421 physicians (360 in private practice, 61 in hospital settings) contributed a mean of 17 patients. Exclusion criteria were age \<18 years and presence of Child B/C cirrhosis. A CONSORT flowchart is provided as [Figure S1](#pone.0107592.s001){ref-type="supplementary-material"}.

Definitions of response {#s2b}
-----------------------

Rapid virological response (RVR) was defined as a negative HCV-RNA (\<50 IU/ml) 4 weeks after begin of therapy (measured between days 25--30 after treatment start). Early Virological response (EVR) was defined as a ≥2 log~10~ decline from baseline in HCV-RNA or as a negative HCV-RNA (\<50 IU/ml) at week 12 (measured between days 74--94). SVR was defined as negative HCV-RNA 24 weeks after end of treatment. The response definitions were the ones used in German and US guidelines [@pone.0107592-Sarrazin1], [@pone.0107592-Ghany1], [@pone.0107592-Strader1]. We are aware that in the recent EASL guideline [@pone.0107592-European1] EVR is defined differently as a HCV-RNA detectable at week 4, but undetectable at week 12.

Statistics {#s2c}
----------

Fisher\'s exact χ^2^-tests without correcting for multiple testing were used to investigate differences between baseline characteristics and the association between various early response categories (at week 4 or week 12) and SVR, respectively. All statistical tests were exploratory and performed at a two-sided significance level of 0.05.

For continuous variables, receiver operating characteristic (ROC) analyses estimated the best cut-off point for prediction of SVR; these were 45 years for age, 400,000 IU/mL for baseline HCV-RNA, 130 mg/dl for total cholesterol, 85 mg/dl for LDL cholesterol, and 3-times elevation of γ-GT above the upper limit of normal (ULN). Categorical variables were used for continuous variables using these cut-off points. Associations with SVR were analyzed by uni- and multivariate means. Liver biopsy or elastography data were available in only a few patients. Thus, the degree of fibrosis was estimated by APRI score [@pone.0107592-Wai1] using three categories: a) \<0.5; b) 0.5--1.5; and c)\>1.5. Values \<0.5 exclude significant fibrosis, values between 0.5--1.5 are associated with mild fibrosis and values\>1.5 with severe fibrosis or cirrhosis [@pone.0107592-Wai1]--[@pone.0107592-Sterling1]. For duration of therapy three categories were used: a) \<22 weeks, b) 22--26 weeks, and c)\>26 weeks [@pone.0107592-Sarrazin1]--[@pone.0107592-Ghany1].

Results {#s3}
=======

Differences in characteristics between GT2 and GT3 patients {#s3a}
-----------------------------------------------------------

GT2 patients were on average 7.1 years older than GT3 patients (p\<0.0001); correspondingly, the estimated duration of infection was 3.8 years longer in GT2 vs. GT3 patients (p\<0.0001). In GT3 patients 69.3% were male whereas in GT2 only 58.6% were male (p\<0.0001). Among GT3 patients drug use accounted for 61.9*%* of infections whereas this infection mode was seen in only 36.8% of GT2 patients (p\<0.0001). Prior administration of blood products accounted for 12.3% of GT2 infections but only for 4.8% of GT3 infections (p\<0.0001) ([Table 1](#pone-0107592-t001){ref-type="table"}).

10.1371/journal.pone.0107592.t001

###### Main characteristics of patients infected with GT2 and GT3.

![](pone.0107592.t001){#pone-0107592-t001-1}

                                              GT2               GT3                   p
  ----------------------------------------- ------- --------- ------- ----------- ----------
  Male gender                                58.6%   229/391   69.3%   601/1956    \<0.0001
  HIV co-infection                           2.6%    10/391    3.2%     62/1956     0.631
  HBV co-infection                           2.3%     9/391    2.2%     43/1956     0.851
  Current drug use                           21.5%   84/391    42.6%   834/1956    \<0.0001
  Drug substitution                          10.5%   41/391    24.8%   486/1956    \<0.0001
  Alcohol abuse \#                           2.3%     9/391    4.8%     93/1956     0.029
  Psychiatric co-morbidity                   14.6%   57/391    16.0%   312/1956     0.534
  Depression                                 10.2%   40/391    12.5%   245/1956     0.235
  Psychosis                                  3.1%    12/391    2.5%     49/1956     0.489
  Psychoanaleptics                           13.3%   52/391    19.9%   390/1956     0.007
  Cardiovascular disease                     10.0%   39/391    4.6%     89/1956    \<0.0001
  Beta-blocking agents                       5.4%    21/391    2.6%     50/1956     0.005
  Calcium channel blockers                   2.3%     9/391    0.6%     11/1956     0.003
  Agents acting on renin-angiotensin         5.4%    21/391    2.4%     47/1956     0.003
  Diabetes mellitus                          5.9%    23/391    1.1%     52/1956     0.002
  Anti-diabetic agents                       4.1%    16/391    1.2%     23/1956    \<0.0001
  *Modes of infection*                                                            
  Blood products                             12.3%   48/391    4.8%     94/1956    \<0.000
  Drug use (i.v. or nasal)                   36.8%   144/391   61.9%   1211/1956   \<0.000
  Sexual transmission                        4.3%    17/391    5.0%     97/1956     0.700
  Tatoos/piercing                            1.8%     7/391    2.5%     48/1956     0.582
  Needle stick                               1.5%     6/391    1.4%     27/1956     0.814
  Surgical/medical procedure                 5.9%    23/301    2.4%     46/1956     0.001
  Medical/dental profession                  1.8%     7/391    0.7%     14/1956     0.068
  Unknown                                    37.9%   148/391   24.3%   476/1956    \<0.000
  SVR                                        64.7%   253/391   56.9%   1112/1956    0.004
  RVR [\*](#nt102){ref-type="table-fn"}      68.2%   131/192   68.0%    613/902     1.000
  EVR [\*\*](#nt103){ref-type="table-fn"}    93.0%   254/273   92.6%   1133/1223    0.898
  SVR in RVR patients                        73.3%   96/131    65.9%    404/613     0.124
  SVR in EVR patients                        72.8%   185/254   66.6%   755/1133     0.056
  Baseline HCV-RNA \> 400.000 IU/ml          58.7%   229/390   50.8%   983/1935     0.004

\# alcohol abuse was assessed by judgement of the physician.

\* only patients who were treated at least for 4 weeks and in whom RVR was correctly determined (see [Methods](#s2){ref-type="sec"} for further details).

\*\* only patients who were treated at least for 12 weeks and in whom EVR was correctly determined (see [Methods](#s2){ref-type="sec"} for further details).

The rate of patients who recently used drugs was higher in GT3 versus GT2 (42.6 vs. 21.5%; p\<0.0001) ([Table 1](#pone-0107592-t001){ref-type="table"}); similarly drug use as an infection mode was also more frequent in GT3 ([Table 1](#pone-0107592-t001){ref-type="table"}). On the other hand the infection modes of blood products, medical procedures and those of unknown etiology were more frequent in GT2 patients when compared with GT3 ([Table 1](#pone-0107592-t001){ref-type="table"}). Although GT2 patients were older, had a longer disease duration and a higher BMI when compared with GT3, the APRI score was higher in GT3 vs. GT2 (1.0 v. 0.8; p = 0.005). The rates of HIV- and HBV-coinfections were similar in the two genotypes as well as the rate of psychiatric comorbidity including depression and psychosis ([Table 1](#pone-0107592-t001){ref-type="table"}). However, GT3 patients had a higher rate of drug substitution and a higher rate of taking psychoanaleptic drugs ([Table 1](#pone-0107592-t001){ref-type="table"}). The rates of most other co-morbidities and co-medications were similar in the two genotypes (data without significant differences not shown) except for cardiovascular disease and diabetes mellitus which were more frequent in GT2 versus GT3. Correspondingly, GT2 patients took antihypertensive agents like beta-blockers, calcium channel blockers, and agents acting on the renin-angiotensin system more frequently ([Table 1](#pone-0107592-t001){ref-type="table"}).

The rate of alcohol abuse was relatively low in both genotypes (\<5%), but higher in patients infected with GT2 versus those infected with GT3 ([Table 1](#pone-0107592-t001){ref-type="table"}). The APRI score was higher in patients with alcohol abuse (1.3±1.2 vs. 1.0±1.3, p = 0.025); this difference in the APRI score was seen tendentially both in GT2 (APRI score with versus without alcohol abuse 1.3±1.8 and 0.8±1.1, p = 0.418), respectively) and in GT3 (APRI score with versus without alcohol abuse 1.3±1.2 and 1.0±1.3, p = 0.070) respectively).

Baseline values for platelets, prothrombine time, ferritin, and γ-GT were not significantly different between genotypes, although platelets and prothrombine time tended to be lower and γ-GT tended to be higher in GT3 when compared with GT2 ([Table 2](#pone-0107592-t002){ref-type="table"}).

10.1371/journal.pone.0107592.t002

###### Main characteristics of patients infected with GT2 and GT3 (Mean).

![](pone.0107592.t002){#pone-0107592-t002-2}

                                   mean    SD     n    mean    SD     n    
  ------------------------------- ------ ------ ----- ------ ------ ------ ----------
  Age (years)                      45.4   12.1   391   38.3   9.6    1956   \<0.0001
  Duration of infection (years)    13.9   10.2   332   10.1   7.8    1743   \<0.0001
  BMI                              25.9   4.7    391   24.9   4.1    1956   \<0.0001
  APRI score                       0.8    1.1    346   1.0    1.3    1780    0.005
  Thrombocytes/nl                  224     75    376   220     72    1885    0.400
  Prothrombine time (%)            97.5   12.0   245   96.9   14.2   1155    0.124
  γ-GT (U/L)                        68    109    370    79    104    1872    0.061
  Cholesterol (mg/dl)              194     40    220   166     53    1037   \<0.0001
  LDL cholesterol (mg/dl)          116     34    120    95     36    532    \<0.0001
  Triglycerides (mg/dl)            130     92    210   119     77    945     0.073
  Ferritin (µg/L)                  193    410    150   165    173    657     0.409
  Duration of therapy (weeks)      24.8   8.8    391   24.4   10.0   1950    0.492
  RBV starting dose (mg/kg/day)    12.6   3.0    390   12.6   3.4    1950    0.767

The mean body mass index (BMI) was higher for GT2 vs. GT3 (25.9 vs. 24.9; p\<0.0001) ([Table 2](#pone-0107592-t002){ref-type="table"}). This difference is not explained by an increase in BMI with older age because this correlation was not statistically significant (data not shown). BMI was similar for both gender in GT2 but higher for males in GT3 ([Table 3](#pone-0107592-t003){ref-type="table"}). Baseline cholesterol was similar for both genders in GT3 but higher for females in GT2. LDL cholesterol was similar for both genders (data not shown). Both total and LDL cholesterol were higher in GT2 when compared with GT3 (194 vs. 166 mg/dl, p\<0.0001; 116 vs. 95 mg/dl, p\<0.001) ([Table 2](#pone-0107592-t002){ref-type="table"}).

10.1371/journal.pone.0107592.t003

###### BMI and baseline cholesterol versus gender.

![](pone.0107592.t003){#pone-0107592-t003-3}

  Body Mass Index (kg/m^2^)                         
  ------------------------------ ----------- ------ ------
  Genotype 2                      p = 0.760         
                                    mean       SD     N
  Male                              25.9      4.0    229
  Female                            26.0      5.5    162
  Total                             25.9      4.7    391
  Genotype 3                      p\<0.0001         
                                    mean       SD     N
  Male                              25.2      3.8    1355
  Female                            24.3      4.6    601
  Total                             24.9      4.1    1956
  Baseline Cholesterol (mg/dl)                      
  Genotype 2                      p = 0.011         
                                    mean       SD     N
  Male                              188.4     40.7   139
  Female                            202.6     37.8    81
  Total                             193.6     40.2   220
  Genotype 3                      p = 0.171         
                                    mean       SD     N
  Male                              164.4     57.3   727
  Female                            169.3     40.7   310
  Total                             165.9     52.9   1037

Differences in BMI, total cholesterol and LDL cholesterol between patients infected with different genotypes are not explained by differences in age and gender because these correlations were not statistically significant (data not shown). Triglyceride levels were not different for GT2 vs. GT3 although the levels were slightly higher in GT2 (130 vs. 119 mg/dl; P = 0.073).

SVR, RVR, and EVR {#s3b}
-----------------

SVR was higher in GT2 when compared with GT3 (64.7 vs. 56.9%, p = 0.004) ([Table 1](#pone-0107592-t001){ref-type="table"}). In GT3 patients SVR was 66.6% in those with an EVR and 21.1% in those without. In GT3 patients without an EVR, therapy was discontinued in week 12 in only 13/90 patients with a SVR of 0/13. Despite the non-response at week 12 and the corresponding stop rule, therapy was continued in 77/90 patients with a SVR of 24.7% (19/77). Of these 19 non-EVR patients with SVR, ten (53%) were treated\>24 weeks (range: 26--52 weeks). In GT2 patients SVR was 72.8% in those with an EVR and 26.3% in those without. In 19 GT2 patients without an EVR therapy was discontinued in week 12 in only five (26.3%) with SVR of 0%. Despite this non-response therapy was continued in 14 of 19 patients resulting in a SVR of 35.7% (5/14). Of five non-EVR patients with SVR four (80%) were treated\>24 weeks (range: 26--52 weeks).

For further EVR analyses we excluded patients who discontinued treatment prior to week 12 as well as those in whom viral load was measured prior to day 74 or later than day 94 after start of treatment. EVR was similar for GT2 and GT3 (93.0 vs. 92.6%, p = 0.9). When assuming similar conditions as explained for EVR, RVR was similar for GT2 vs. GT3 (68.2 vs. 68.0%; p = 1.0).

We also determined in how many patients EVR was measured according to the German and EASL guidelines; for this analysis we excluded patients who discontinued treatment prior to week 12. It was also assumed that EVR was not correctly assessed when HCV-RNA was measured prior to day 74 or later than day 94. EVR was correctly determined in 273/372 patients (73.4%) for GT2 and in 1,223/1,894 patients (64.6%) for GT3. When assuming similar conditions as explained for EVR, RVR was correctly determined in 902/1,895 GT3 patients (47,6%) and in 192/388 GT2 patients (49.5%). Detailed data on the number of patients in whom EVR and RVR were determined correctly, i.e. as suggested by the corresponding guidelines, are given in [Table 1](#pone-0107592-t001){ref-type="table"}.

SVR in patients with EVR or RVR was also determined by excluding the type of patients explained above. For GT3 SVR was 65.9% in patients with RVR and 48.4% in patients without. For GT2 SVR was 73.3% in patients with RVR and 44.3% in patients without.

Total duration of treatment and initial RBV doses were similar for both genotypes ([Table 2](#pone-0107592-t002){ref-type="table"}). Subtypes of genotypes were associated with SVR in neither GT2 nor GT3 (data not shown).

When SVR was calculated only for patients with a planned end of therapy or with a discontinuation because of virological failure or side-effects, SVR was 70.5% for GT2 (253/359) and 67.6% for GT3 (1,112/1,645) (p = 0.317); when these results are compared with SVR in the total group, SVR is increased by 10.7% in GT3 but only by 5.8% in GT2 when applying this type of analysis. We therefore looked for genotype-specific differences in the follow-up of patients with an end-of-treatment (EOT) response. Of the total 1,454 GT3 patients with an EOT response, SVR was not determined in 209 patients (14.4%), in particular because patients were lost to follow-up. In contrast, SVR was not determined for such reason in only 27 of 315 GT2 patients (8.6%).

Further analyses looked for explanations for these genotype-specific differences. One analysis looked at the correlation between genotype and mode of infection, revealing that patients with an infection mode of drug use had a lower SVR than those with other infection modes for GT3 but not for GT2 ([Table 4](#pone-0107592-t004){ref-type="table"}). In addition, we analyzed the loss to follow-up in EOT responders in relation to their infection mode. The highest loss to follow-up was seen in patients with drug use as the infection mode with 12.5 and 15.1% in GT2 and GT3, respectively; these percentages were higher when compared to patients with other infection modes (4.4 and 8.2% for GT2 and GT3; p = 0.008 and p\<0.0001, respectively).

10.1371/journal.pone.0107592.t004

###### SVR versus mode of infection in GT2 and GT3 patients.

![](pone.0107592.t004){#pone-0107592-t004-4}

                                Genotype 2   Genotype 3                                          
  ---------------------------- ------------ ------------ ----- ------ ------- ----- ------ ----- ------
  Blood products                    15          31.3      33    68.8   0.629   35    37.2   59    62.8
  Drug use (i.v. or nasal)          58          40.3      86    59.7   0.100   550   45.4   661   54.6
  Sexual transmission               7           41.2      10    58.8   0.609   42    43.3   55    56.7
  Tatoos/piercing                   3           42.9       4    57.1   0.700   21    43.8   27    56.3
  Needle stick                      3           50.0       3    50.0   0.427   11    40.7   16    59.3
  Surgical/medical procedure        9           39.1      14    60.9   0.659   13    28.3   33    71.7
  Medical/dental profession         1           14.3       6    85.7   0.429    4    28.6   10    71.4
  Unknown                           46          31.1      102   68.9   0.227   187   39.3   289   60.7

(multiple answers allowed; differences between modes of infections in GT2 versus GT3 were tested for significance by Fisher\'s exact χ^2^-test without correcting for multiple testing).

Because of the low rate of determining EVR, we looked whether this phenomenon might be due to the fact that physicians did not determine HCV-RNA at week 12 when an RVR had been documented in week 4. Interestingly, in GT3 EVR was correctly determined in 666/856 patients in whom RVR was measured (77.8%), while EVR was not determined in 228/401 patients (56.9%) in whom RVR was not determined. This phenomenon was similar for GT2 (data not shown).

Four out of five GT2 EVR non-responders with a SVR were treated\>26 weeks; two of them had a SVR when treated with\>800 mg RBV. Ten of 19 GT3 EVR non-responders with a SVR were treated\>26 weeks (52.6%) and ten of 19 GT3 EVR non-responders received a RBV dose\>800 mg (52.6%).

In this non-interventional study IL28 genotype was determined rarely, in 72/1,956 GT3 patients (3.7%) (CC 70.8, CT 22.2, TT 6.9%) and in 14/391 GT2 patients (3.6%) (CC 71.4, CT 21.4, TT 7.1%). In GT 2 SVR was 60% (6/10) in IL28 CC and 75% (3/4) in IL28 non-CC (p = 0.868); in GT3 SVR was 72.5% (51/67) in IL28 CC and 47.6% (10/21) in IL28 non-CC (p = 0.051).

Variables predicting SVR {#s3c}
------------------------

By univariate analysis of GT2 patients, at baseline a high prothrombine time, a low APRI score, and a γ-GT ≤3-times the ULN predicted SVR; RVR and RBV starting dose were also associated with SVR ([Table 5](#pone-0107592-t005){ref-type="table"}). By multivariate analysis only a low γ-GT and RVR were associated with SVR ([Table 6](#pone-0107592-t006){ref-type="table"}).

10.1371/journal.pone.0107592.t005

###### Univariate analysis of variables for prediction of SVR in GT2 and GT3.

![](pone.0107592.t005){#pone-0107592-t005-5}

                                                               Genotype 2   Genotype 3                                                        
  ----------------------------------------------------------- ------------ ------------ ------- ------- ----- ------- ------- ------- ------- -----------------------------------------
  Gender                                                         0.805                                   391   0.156                                            1956
  Age ≤45 vs.\>45 years                                          0.842                                   391   0.014   0.781   0.642   0.950                    1956
  BMI                                                            0.843                                   391   0.364                                            1956
  Subtype of HCV genotype                                        0.381                                   224   0.753                                            1332
  Duration of infection (years)                                  0.910                                   332   0.800                                            1743
  HCV-RNA ≤400,000 vs.\>400,000 IU/ml                            0.458                                   390   0.045   0.832   0.695   0.996                    1935
  Psychiatric co-morbidity                                       0.972                                   391   0.022   0.754   0.591   0.960                    1956
  HIV co-infection                                               0.752                                   391   0.558                                            1956
  HBV co-infection                                               0.406                                   391   0.166                                            1956
  Current drug use                                               0.388                                   391   0.063                                            1956
  LDL cholesterol ≤85 vs.\>85 mg/dl                              0.308                                   120   0.000   2.073   1.456   2.951                     532
  Cholesterol ≤130 vs.\>130 mg/dl                                0.332                                   220   0.000   1.838   1.360   2.483                    1037
  Triglycerides (mg/dl)                                          0.962                                   210   0.564                                             945
  Serum ferritin (µg/l)                                          0.075                                   150   0.206                                             657
  Prothrombine time (%)                                          0.007        1.032      1.009   1.055   245   0.138                                            1155
  APRI score \<0.5; 0.5-≤1.5; 1.5-≤2 \#                          0.050        0.783      0.613   1.000   346   0.000   0.764   0.689   0.846                    1780
  γ-GT\> vs. ≤3-times ULN                                        0.017        0.392      0.182   0.844   370   0.000   0.480   0.347   0.663                    1872
  **Variables under treatment**                                                                                                               
  RVR                                                            0.000        3.759      2.004   7.052   195   0.000   2.900   2.210   3.803                     963
  Duration of therapy \<22 weeks - 22--26 weeks -\>26 weeks      0.247                                   359   0.732                           1643[\*\*](#nt106){ref-type="table-fn"}
  Change in dose PEG-interferon                                  0.326                                   391   0.140                                            1953
  RBV starting dose (mg/kg body weight)                          0.002        1.127      1.046   1.213   390   0.004   1.041   1.013   1.069                    1950

\* OR  =  Odds Ratio; CI  =  Confidence interval.

\*\* With a planned treatment end or with treatment discontinuation for virological failure or adverse events.

\# By univariate analysis baseline thrombocytes and GOT were also significant in GT3 in predicting SVR; in GT2 these variables were not significant. Since the APRI score which combines these two variables had a higher predictive value when compared with the two single variables only the APRI score was used for further analyses.

10.1371/journal.pone.0107592.t006

###### Multivariate analysis of variables for prediction of SVR in GT2 and GT3.

![](pone.0107592.t006){#pone-0107592-t006-6}

                                                                                                    Genotype 2   Genotype 3                                          
  ------------------------------------------------------------------------------------------------ ------------ ------------ ------- ------- ------- ------- ------- -------
  Age ≤45 years vs.\>45 years                                                                                                                 0.001   0.613   0.460   0.817
  Cholesterol ≤130 vs.\>130 mg/dl                                                                                                             0.001   1.768   1.277   2.446
  γ-GT (U/l)\> vs. ≤3 time ULN                                                                        0.011        0.341      0.148   0.785   0.030   0.585   0.361   0.950
  APRI score \<0.5. 0.5 - ≤1.5. 1.5 - ≤2                                                              0.269                                   0.002   0.786   0.673   0.917
  HCV-RNA ≤400,000 vs.\>400,000 IU/ml                                                                                                         0.780                  
  Psychiatric co-morbidity                                                                                                                    0.165                  
  **Variables under treatment in patients with complete data** [\*](#nt108){ref-type="table-fn"}                                                                     
  RVR                                                                                                 0.000        3.770      1.930   7.362   0.001   1.63    1.212   2.203
  Ribavirin starting dose (mg/kg body weight)                                                         0.256                                   0.006   1.069   1.208   2.198

\* For GT3 complete baseline data for multivariate analysis were available for 968 patients and in 341 patients with GT2; complete data under treatment were available for 787 patients with GT3 and for 180 patients with GT2.

OR  =  Odds Ratio; CI  =  Confidence interval.

In GT3 univariate analysis showed that several baseline variables were associated with SVR: age ≤45 years, total cholesterol\>130 mg/dl, LDL cholesterol\>85 mg/dl, HCV-RNA ≤400,000 IU/mL, low APRI score, γ-GT ≤3-times ULN and absence of psychiatric co-morbidity ([Table 5](#pone-0107592-t005){ref-type="table"}). By multivariate analysis age ≤45 years, total cholesterol\>130 mg/dl, low APRI score and γ-GT ≥3-times ULN were associated with SVR but not HCV-RNA and psychiatric co-morbidity ([Table 6](#pone-0107592-t006){ref-type="table"}). RVR and RBV starting dose were associated with SVR by uni- and multivariate analysis in GT3 ([Table 6](#pone-0107592-t006){ref-type="table"}).

We also did a GT3 multivariate analysis including both total and LDL cholesterol showing that total cholesterol was still significant (p\<0.0001) but not LDL cholesterol (p = 0.106) (data not shown). Since LDL was only measured in ¼ of patients, we present multivariate analyses in [Table 6](#pone-0107592-t006){ref-type="table"} without including LDL data.

Discussion {#s4}
==========

Treatment algorithms have been similar for GT2 and GT3 in German, EASL and AASLD guidelines recommending PEG-IFN and RBV at a flat dose of 800 mg/day for 24 weeks [@pone.0107592-Sarrazin1]--[@pone.0107592-Ghany1]. Studies with DAAs have been successful for GT2, whereas SVR appears to be lower in GT3 [@pone.0107592-Lawitz1]--[@pone.0107592-Mauss1]. Recently, sofosbuvir has been approved as the first DAA for patients with GT2 and GT3. Major differences in the response to sofosbuvir-based therapy in GT2 versus GT3 patients remain. These latter data further emphasize that the two genotypes differ in many important aspects [@pone.0107592-Jacobson1]. It is unclear in which countries DAAs like sofosbuvir will be reimbursed in view of economic problems [@pone.0107592-Petta2]. In countries with reimbursement issues therapy with PEG-IFN and RBV will remain the standard. Therefore, it is crucial to optimize this therapy.

It has recently been suggested that GT2 and GT3 differ in various aspects and need more specific management [@pone.0107592-Slavenburg1]--[@pone.0107592-Probst1]. In particular, it has been shown that SVR appears to be higher and relapse rate to be lower in GT2 when compared with GT3 [@pone.0107592-Shiffman1], [@pone.0107592-Sarin1], [@pone.0107592-Brown1]. In addition, GT3 has been suggested to cause a more rapid progression towards fibrosis when compared with GT2 [@pone.0107592-Probst1], [@pone.0107592-Bochud1]--[@pone.0107592-Backus1]. GT3 induces a specific interaction with cholesterol metabolism and a specific type of hepatic steatosis [@pone.0107592-Felmlee1]. GT3 is often associated with a history of drug abuse and adherence problems [@pone.0107592-Cacoub1]. There is still a controversy which subgroups of GT2 and GT3 patients need a shortened or prolonged therapy and RBV dosing adapted to body weight [@pone.0107592-Slavenburg1], [@pone.0107592-Andriulli1]--[@pone.0107592-Pedersen1]. There is some agreement that treatment shortening should be reserved to patients with RVR and low baseline viral load and that prolongation to those without RVR and with further negative predictive factors [@pone.0107592-Sarrazin1]--[@pone.0107592-Ghany1], [@pone.0107592-Shiffman1], [@pone.0107592-Petta1]. In previous studies lack of fibrosis predicted SVR, as well as young age and a HCV-RNA \<400,000--600,000 IU/ml [@pone.0107592-Dalgard1]--[@pone.0107592-Mangia2]. Some studies showed that low BMI [@pone.0107592-Mangia1], [@pone.0107592-Shiffman1] was associated with a high SVR. In addition high γ-GT and low platelets appeared to be associated with a low SVR [@pone.0107592-Mecenate1], [@pone.0107592-Probst1]. RVR predicted SVR both in GT2 and GT3 [@pone.0107592-Mangia1], [@pone.0107592-Dalgard2], [@pone.0107592-Mangia2]--[@pone.0107592-Mecenate1].

The present large real-life study shows that there are many important differences between GT2 and GT3 patients. GT3 patients are younger, have a shorter duration of infection and are more likely to be male than GT2 patients. The predominant mode of infection was drug use in GT3, whereas prior administration of blood products had been documented more often in GT2. The differences in infection modes may partly explain differences in age, gender, and disease duration between patients infected with different genoytpes. Although GT2 patients were older, had a longer disease duration and a higher BMI when compared with GT3, the APRI score and thus the severity of fibrosis was higher in GT3 vs. GT2. This data corroborates that fibrosis progresses more rapidly in GT3 when compared with other genotypes [@pone.0107592-Probst1], [@pone.0107592-Bochud1]--[@pone.0107592-Backus1]. Since alcohol abuse was more frequent in patients infected with GT3 versus GT2, alcohol might be a co-factor for the more rapid fibrosis in GT3. However, alcohol abuse is probably not the only explanation for the latter finding because alcohol abuse was seen in less than 5% of patients with either genotype.

In our large real-life cohort SVR in GT2 (64.7%) and GT3 (56.9%) appears relatively low when compared with previous controlled trials [@pone.0107592-Hadziyannis1]--[@pone.0107592-Mecenate1]; in line with previous studies SVR was higher in GT2 when compared with GT3. When SVR was calculated only for patients with a planned end of therapy or with a discontinuation because of virological failure or side-effects, SVR was increased by more than 10% in GT3 but only by about 6% in GT2 when compared with the total cohort. Further analyses showed that many GT3 patients with an EOT response were lost to follow-up and thus counted as having no SVR, whereas this phenomenon was less pronounced in GT2. Additional calculations revealed that GT3 patients with an infection mode of drug use had a lower SVR and a higher loss to follow-up than those with other modes of infection. Thus, in particular the relatively low SVR in GT3 is partly explained by loss of follow-up after EOT in patients with a drug history. This data confirms that some GT3 patients have adherence problems [@pone.0107592-Cacoub1]. Such adherence issues may also be important in light of new DAA therapies including sofosbuvir of which one tablet costs more than 700 Euro in most European countries.

We are aware that several studies showed that drug adherence and SVR may be quite good also in patients with drug use and in those with methadone maintenance [@pone.0107592-Mauss1]--[@pone.0107592-Bonkovsky1]. Most of these studies, however, were done in clinical trial settings. Some studies showed that SVR was somewhat lower in patients with methadone maintenance when compared to that expected for controls [@pone.0107592-Mauss1]--[@pone.0107592-Lindenburg1]. In addition, a controlled study in methadone-substituted patients showed that SVR was markedly better with direct observed therapy versus self-administration of pegylated interferon [@pone.0107592-Bonkovsky1]. Thus, even when considering the latter studies we suggest from the present real-world findings that some GT3 patients with a drug history have adherence problems which may reduce SVR. One reason could be that treatment under real-life conditions includes less experienced physicians without a well integrated internist-addiction medicine [@pone.0107592-Martinez1].

In the present cohort, RVR was determined in only about 70% of patients and EVR in only about 50% for both genotypes. Thus, some physicians tend to care neither for shortening of therapy (by not measuring RVR) nor for the stop rule at week 12 (by not measuring EVR). The physicians who do not care for shortening and those who do not care for stop rules tend to be the same. They for patients 24 weeks regardless of viral kinetics. In patients without an EVR most physicians continued treatment with SVR rates exceeding 20%; these SVR values in EVR non-responders are 10-times higher than those reported in RCTs (literature in [@pone.0107592-Sarrazin1]--[@pone.0107592-Ghany1]). This data is similar to what we have recently reported in a real-life GT1 cohort [@pone.0107592-Niederau2]. In the GT1 cohort we identified factors explaining the high SVR in EVR non-responders in whom treatment was continued despite stop rules [@pone.0107592-Niederau2]. This was partly due to the fact that reductions in PEG-IFN or RBV doses were not performed despite recommendations which are strictly observed in RCTs. We did not assess the latter association in the present cohort because it has a different focus. Nevertheless, the present analysis again shows that it is insufficient to only base guidelines on RCTs which may not mirror clinical reality. The present real-life data also suggests that therapy\>24 weeks and a weight-adapted RBV dose may be helpful for patients with a slow initial virological response.

In this non-interventional study, IL28 genotype was determined rarely, and therefore this data was not included in analyses for prediction of SVR. Nevertheless, the present data is still interesting by showing that measurement of IL28 genotype is not considered important in the broad medical community in Germany for GT2 and GT3 although there is no reimbursement problem for this determination. Since IL28 was measured only in a small fraction of the GT2 and GT3 patients we do not discuss potential differences of IL28 data between the two genotypes. HCV interferes with several pathways of lipid metabolism [@pone.0107592-Felmlee1], [@pone.0107592-Barth1]--[@pone.0107592-Syed1]. Steatosis is seen in up to half of patients infected with GT3 [@pone.0107592-Sanyal1]--[@pone.0107592-RubbiaBrandt1]; it is directly linked to HCV and often resolves after SVR [@pone.0107592-Hezode1]--[@pone.0107592-Patton1]. It has recently been shown that total cholesterol but not triglycerides were lower in patients with GT3 when compared to GT2 [@pone.0107592-Clark1]. Obesity and insulin-resistance are risk factors for steatosis and fibrosis and decrease the chance for SVR in GT1 [@pone.0107592-Sanyal1], [@pone.0107592-Hezode1], [@pone.0107592-Serfaty1]--[@pone.0107592-Corey1]. High LDL and cholesterol values as well statin use have been associated with a good SVR in GT1 [@pone.0107592-Clark1], [@pone.0107592-Ramcharran1]--[@pone.0107592-Harrison1]. To our knowledge, it has not been reported previously that high values of total and LDL cholesterol are strong predictors for SVR also in GT3, whereas this association is not seen in GT2. In our large cohort we corroborate the findings by Clark et al. [@pone.0107592-Clark1] showing that both total cholesterol and LDL are markedly lower in GT3 when compared to GT2. The present finding that BMI is higher in patients infected with GT2 versus GT3 was unexpected. We suggest that our results are valid because the statistical difference was large and we also identified that cardiovascular disease, diabetes mellitus, and the use of anti-hypertensive drugs were more frequent in GT2 versus GT3 patients.

In summary, the present study confirms that liver fibrosis is more pronounced in GT3 vs. GT2. SVR is higher in GT2 vs. GT3 partly because of follow-up problems in GT3 patients and in particular in those who had been infected by drug use. Thus, subgroups of GT3 patients have adherence problems and are difficult to treat; these patients may have significant liver fibrosis and need special attention and education as well as intensified treatment.
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